TransMedics Group (NASDAQ: TMDX) is one of 51 publicly-traded companies in the “Electromedical equipment” industry, but how does it compare to its competitors? We will compare TransMedics Group to related businesses based on the strength of its valuation, risk, dividends, analyst recommendations, earnings, profitability and institutional ownership.

Valuation and Earnings

This table compares TransMedics Group and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
TransMedics Group $23.60 million -$33.55 million -5.53
TransMedics Group Competitors $1.12 billion $126.03 million 16.94

TransMedics Group’s competitors have higher revenue and earnings than TransMedics Group. TransMedics Group is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

70.7% of TransMedics Group shares are held by institutional investors. Comparatively, 47.2% of shares of all “Electromedical equipment” companies are held by institutional investors. 15.5% of shares of all “Electromedical equipment” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.


This table compares TransMedics Group and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
TransMedics Group -142.12% N/A -35.53%
TransMedics Group Competitors -233.15% -74.62% -10.50%

Analyst Recommendations

This is a breakdown of recent ratings for TransMedics Group and its competitors, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TransMedics Group 0 1 3 0 2.75
TransMedics Group Competitors 332 872 1542 80 2.48

TransMedics Group currently has a consensus target price of $28.75, indicating a potential upside of 120.48%. As a group, “Electromedical equipment” companies have a potential upside of 56.36%. Given TransMedics Group’s stronger consensus rating and higher possible upside, equities research analysts clearly believe TransMedics Group is more favorable than its competitors.

TransMedics Group Company Profile

TransMedics, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. The company offers Organ Care System (OCS), an integrated, compact, portable preservation technology that addresses unmet need for organs for transplantation. Its Organ Care System preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. Its Organ Care System incudes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains organs in a near physiologic state and enables surgeons to perfuse and ventilate the organ between the donor and recipient sites; OCS Heart, a portable heart perfusion system that helps to maintain organs in a warm functioning state outside of the body; and OCS Liver, a portable perfusion and monitoring system that maintains organs in a near physiologic state. The company offers its products in the United States and internationally. TransMedics, Inc. is headquartered in Andover, Massachusetts. TransMedics, Inc. is a subsidiary of Transmedics Group, Inc.

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with's FREE daily email newsletter.